The Delhi High Court is reviewing Natco Pharma’s challenge to a breast cancer drug patent. Natco alleges Novartis and Astex secured two patents for the same invention. This action, Natco claims, unlawfully extends patent protection for the Ribociclib molecule. The court will first determine the petition’s maintainability after legal arguments. The case has been scheduled for further hearing on September 16.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.